CTLA4 and colitis: This is supported by the study by Wang et al. who found that the administration of L. reuteri inhibits the development and progression of immune checkpoint blocker (ICB)-induced colitis (which enhances antitumor immunity by blocking CTLA-4), and that the depletion of Lactobacillus by antibiotic therapy worsens ICB colitis [21].